Title:
FUSED RING COMPOUNDS SERVING AS HPK1 INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2023/134608
Kind Code:
A1
Abstract:
Provided is a class of fused ring compounds that serve as HPK1 inhibitors. Specifically, provided are a compound represented by general formula (1), a preparation method therefor, and a use of the compound of general formula (1) and isomers, crystal forms, a pharmaceutically acceptable salt, a hydrate, or a solvate thereof as an HPK1 inhibitor. The compound as well as the isomers, crystal forms, pharmaceutically acceptable salt, hydrate, or solvate thereof can be used for preparing a drug for treating or preventing diseases related to HPK1 mediation.
Inventors:
XIE YULI (CN)
LIU WENZHONG (CN)
QIAN LIHUI (CN)
LIU WENZHONG (CN)
QIAN LIHUI (CN)
Application Number:
PCT/CN2023/071184
Publication Date:
July 20, 2023
Filing Date:
January 09, 2023
Export Citation:
Assignee:
WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN)
International Classes:
C07D403/14; A61K31/506; A61K31/5355; A61K31/541; A61P35/00; A61P37/00; C07D405/14; C07D409/14; C07D413/14; C07D417/14
Domestic Patent References:
| WO2021000935A1 | 2021-01-07 | |||
| WO2021032148A1 | 2021-02-25 | |||
| WO2011120026A1 | 2011-09-29 |
Foreign References:
| CN110402248A | 2019-11-01 |
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: